Skip to main content
. 2021 Oct 20;11:716246. doi: 10.3389/fonc.2021.716246

Figure 4.

Figure 4

HPV16 E6 promotes ST6GAL1 expression by activating Hippo signaling pathway. (A) Dysregulated mRNAs between C33A and C33A-E6 (E6 stable expressing) cells were detected by mRNA sequencing. (B) Heat map and hierarchical clustering analysis of 658 dysregulated mRNAs with three independent biological replicates were presented. (C) Venn diagram of 658 E6-dysregulated mRNAs and 6,913 ST6GAL1-asscociated mRNAs in TCGA dataset (N = 305). ST6GAL1-associated mRNAs were identified using R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). (D) KEGG enrichment analysis of 466 mRNAs that simultaneously associated with E6 and ST6GAL1. (E) C33A and C33A-E6 cells were treated with verteporfin (5 μM, Hippo signaling inhibitor), ODQ (10 μM, cGMP/PKG inhibitor), and LY-364947 (5 μM, TGF-β inhibitor) for 24 h, and then, qRT-PCR was used to detect ST6GAL1 mRNA expression. DMSO was used as solvent control. ST6GAL1 protein expression of C33A and C33A-E6 cells in response to (F) verteporfin, (G) ODQ, and (H) LY-364947 treatment was detected by Western blot. Data were presented as mean ± SD from the three independent replicates. ***p < 0.001.